M
Mark S. Carey
Researcher at University of British Columbia
Publications - 85
Citations - 9825
Mark S. Carey is an academic researcher from University of British Columbia. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 33, co-authored 74 publications receiving 8306 citations. Previous affiliations of Mark S. Carey include BC Cancer Agency & Vancouver Coastal Health.
Papers
More filters
Journal ArticleDOI
A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J. Perren,Ann Marie Swart,Jacobus Pfisterer,Jonathan A. Ledermann,Eric Pujade-Lauraine,Gunnar B. Kristensen,Mark S. Carey,Philip Beale,Andrés Cervantes,Christian Kurzeder,Andreas du Bois,Jalid Sehouli,Rainer Kimmig,A. Stähle,Fiona Collinson,Sharadah Essapen,Charlie Gourley,Alain Lortholary,Frédéric Selle,Mansoor Raza Mirza,Arto Leminen,Marie Plante,Dan Stark,Wendi Qian,Wendi Qian,Mahesh K. B. Parmar,Amit M. Oza,Icon investigators +27 more
TL;DR: In patients at high risk for progression, the benefit was greater with bevacizumab than without it, with progression-free survival (restricted mean) at 42 months of 14.5 months, higher than the average for women with ovarian cancer.
Journal ArticleDOI
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth
Kristin M Nieman,Hilary A. Kenny,Carla Penicka,Andras Ladanyi,Rebecca Buell-Gutbrod,Marion Zillhardt,Iris L. Romero,Mark S. Carey,Gordon B. Mills,Gökhan S. Hotamisligil,S. Diane Yamada,Marcus E. Peter,Katja Gwin,Ernst Lengyel +13 more
TL;DR: It is shown that primary human omental adipocytes promote homing, migration and invasion of ovarian cancer cells, and that adipokines including interleukin-8 (IL-8) mediate these activities, and adipocytes provide fatty acids for rapid tumor growth.
Journal ArticleDOI
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Katherine Stemke-Hale,Ana M. Gonzalez-Angulo,Ana Lluch,Richard M. Neve,Wen Lin Kuo,Michael Davies,Mark S. Carey,Zhi Hu,Yinghui Guan,Aysegul A. Sahin,W. Fraser Symmans,Lajos Pusztai,Laura K. Nolden,Hugo M. Horlings,Katrien Berns,Mien Chie Hung,Marc J. van de Vijver,Vicente Valero,Joe W. Gray,René Bernards,Gordon B. Mills,Bryan T. Hennessy +21 more
TL;DR: PI3K pathway aberrations likely play a distinct role in the pathogenesis of different breast cancer subtypes and the specific aberration present may have implications for the selection of PI3K-targeted therapies in hormone receptor-positive breast cancer.
Journal ArticleDOI
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
Bryan T. Hennessy,Ana M. Gonzalez-Angulo,Katherine Stemke-Hale,Michael Z. Gilcrease,Savitri Krishnamurthy,Ju Seog Lee,Jane Fridlyand,Aysegul A. Sahin,Roshan Agarwal,Corwin Joy,Wenbin Liu,David N. Stivers,Keith A. Baggerly,Mark S. Carey,Ana Lluch,Carlos Monteagudo,Xiaping He,Victor J. Weigman,Cheng Fan,Juan P. Palazzo,Gabriel N. Hortobagyi,Laura K. Nolden,Nicholas J. Wang,Vicente Valero,Joe W. Gray,Charles M. Perou,Gordon B. Mills +26 more
TL;DR: Metaplastic breast cancers (MBCs) are aggressive, chemoresistant tumors characterized by lineage plasticity as discussed by the authors, and they have unique DNA copy number aberrations compared with common breast cancers.
Journal ArticleDOI
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Amit M. Oza,Adrian Cook,Jacobus Pfisterer,Andrew C. Embleton,Jonathan A. Ledermann,Eric Pujade-Lauraine,Gunnar B. Kristensen,Mark S. Carey,Philip Beale,Andrés Cervantes,Tjoung Won Park-Simon,Gordon J. S. Rustin,Florence Joly,Mansoor Raza Mirza,Marie Plante,Michael A. Quinn,Andres Poveda,Gordon C Jayson,Dan Stark,Ann Marie Swart,Laura Farrelly,Richard Kaplan,Mahesh K. B. Parmar,Timothy J. Perren +23 more
TL;DR: The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression, so evidence of non-proportional hazards was shown.